Skip to content
Inciteful Med

Building Your Care Team and Monitoring

Last updated:

Managing an endocrine or neuroendocrine tumor requires a multidisciplinary care team, including endocrinologists and oncologists. Long-term surveillance involves regular imaging, biomarker testing, and potentially lifelong hormone replacement therapy if glands are surgically removed.

Key Takeaways

  • • Endocrine and neuroendocrine tumors are best managed by a multidisciplinary tumor board of varied specialists.
  • • Your core care team should include endocrinologists, surgical oncologists, medical oncologists, and nuclear medicine specialists.
  • • Long-term surveillance is critical and involves regular imaging and blood or urine tests to check tumor markers.
  • • Surgical removal of endocrine glands often requires lifelong, carefully monitored hormone replacement therapy.
  • • Bring your actual digital imaging discs, detailed pathology reports, and a symptom log to your first consultation.

Managing an endocrine or neuroendocrine tumor (NET) is rarely a one-person job. Because these tumors affect both the physical structure of your organs and the chemical balance of your body, they require a multidisciplinary care team. This team works together to ensure that every aspect of your health—from surgery to hormone replacement—is addressed [1][2][3].

The Power of the Multidisciplinary Tumor Board (MDT)

An MDT is a regular meeting where specialists from different fields sit down together to review your specific case [1][4]. This “brain trust” approach is essential because it allows for a second look at your pathology, a joint review of your imaging, and a consensus on the best treatment path [5][6][7]. Research shows that patients whose cases are reviewed by an MDT often have better outcomes and access to a wider range of treatment options [1][8][9].

Your Core Specialists

  • Endocrinologist: The expert in your body’s hormones. They manage hormone excess symptoms before surgery and replacement therapy afterward [2][10].
  • Surgical Oncologist / Endocrine Surgeon: The specialist who performs the surgery to remove the tumor or debulk the disease [2][4].
  • Medical Oncologist: The doctor who coordinates systemic treatments like chemotherapy, targeted therapies, or somatostatin analogs [2][11].
  • Nuclear Medicine Specialist: A crucial member who handles specialized functional imaging (like DOTATATE PET scans) and targeted radiation treatments like PRRT [2][12].
  • Pathologist & Radiologist: The “behind-the-scenes” experts who identify the tumor’s grade and map its exact location [2][5][6].

What to Expect: A General Timeline

Navigating a new diagnosis can be overwhelming. Here is a typical sequence of events:

  1. Initial Discovery: Symptoms or an incidental finding on a scan prompts investigation.
  2. Biochemical Workup: Blood and urine tests to determine if the tumor is “functional” (secreting hormones).
  3. Specialized Imaging: Advanced scans (like MRI or DOTATATE PET) to map the exact location and spread.
  4. Tumor Board Review: Your MDT meets to review your pathology, labs, and scans to build a consensus plan.
  5. Treatment Execution: Ranging from surgical resection to targeted radiation or medical management.
  6. Long-Term Surveillance: Ongoing monitoring of tumor markers and hormone levels.

Long-Term Surveillance and Survivorship

Once the initial treatment is complete, you enter the “surveillance” phase. Because some endocrine tumors can recur many years later, long-term follow-up is vital [13][14].

1. Monitoring Schedules

Typical surveillance involves a combination of blood/urine tests (checking markers like Chromogranin A or hormone levels) and imaging (CT, MRI, or PET scans) [15][16][17]. The frequency of these scans depends on your tumor’s grade; for example, Grade 2 tumors require more frequent follow-up than small, low-grade ones [14][13].

2. Lifelong Hormone Replacement

If a gland is partially or fully removed, your body may no longer produce the hormones you need to function. You may require lifelong replacement therapy:

  • Thyroidectomy: Requires levothyroxine (L-T4) to replace thyroid hormone [18][19].
  • Adrenal or Pituitary Surgery: May require hydrocortisone (to replace cortisol) or desmopressin (DDAVP) to manage water balance [20][21][22].
  • Pancreatic Surgery: May lead to a need for insulin or digestive enzymes [3].

Please note: Finding the correct hormone replacement dosage is not an instant fix. It takes time, patience, and frequent blood tests to get the levels just right. Do not get discouraged if you feel “off” while your team adjusts your dose.

Preparing for Your First Consultation

To make the most of your first visit with a multidisciplinary team, come prepared with your complete medical record. This includes [23][24]:

  • Imaging Discs: Bring the actual digital files (DICOM format) of your CT, MRI, and PET scans, not just the written reports [5].
  • Pathology Reports: The detailed “fine print” describing your tumor’s grade and Ki-67 index [23][25].
  • Lab Results: All recent blood and urine tests showing your hormone and biomarker levels [17][26].
  • Symptom Log: A record of any “spells,” fatigue, or changes in your mood or energy [17].

Frequently Asked Questions

What specialists should be on my neuroendocrine tumor care team?
Your multidisciplinary care team should include an endocrinologist, a surgical oncologist or endocrine surgeon, a medical oncologist, and a nuclear medicine specialist. Pathologists and radiologists also play a crucial behind-the-scenes role in your care.
Why is a multidisciplinary tumor board important for endocrine tumors?
A tumor board brings together experts from different medical fields to review your specific case, including your pathology and imaging. Research shows this collaborative approach leads to better outcomes and provides access to a wider range of treatment options.
What kind of long-term monitoring is needed after endocrine tumor treatment?
Surveillance typically involves a combination of regular blood and urine tests to check tumor markers and hormone levels, along with imaging like CT, MRI, or PET scans. The frequency of these tests depends on the grade of your tumor.
Will I need lifelong hormone replacement after tumor surgery?
If an endocrine gland is partially or completely removed during surgery, you may need lifelong hormone replacement therapy. Finding the correct dosage takes time, patience, and frequent blood tests to ensure your body's levels are properly balanced.
What should I bring to my first consultation with a new oncology team?
You should bring your complete medical records, including digital files of your imaging scans on a disc, your detailed pathology reports, recent lab results, and a detailed log of any symptoms you have been experiencing.

Questions for Your Doctor

  • • Who are the specific members of my Multidisciplinary Tumor Board (MDT), and will an endocrinologist and a nuclear medicine specialist be involved in my care?
  • • Does your center have a high volume of experience treating my specific type of endocrine tumor?
  • • What is the long-term surveillance schedule for me (e.g., how often will I need scans and blood tests)?
  • • If my tumor is removed, which hormones (like levothyroxine or hydrocortisone) will I need to replace, and how do we safely monitor those levels?
  • • Can you provide a 'survivorship plan' that outlines who manages my long-term monitoring—my oncologist or my endocrinologist?
  • • Are there clinical trials or advanced treatments like PRRT that our MDT is considering for my case?

Questions for You

  • • Do I have a dedicated folder or digital drive with my pathology reports, laboratory results, and copies of my actual imaging discs (not just the written reports)?
  • • How am I feeling physically and emotionally between scans, and have I shared any 'scanxiety' with my care team?
  • • Am I keeping a log of any new or changing symptoms, like sudden fatigue, mood shifts, or changes in my heart rate, to share at my next visit?
  • • Who is my 'point person' or nurse navigator on the care team that I can contact if I have urgent questions about my hormone levels?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome.

    Freytag M, Herrlinger U, Hauser S, et al.

    BMC cancer 2020; (20(1)):355 doi:10.1186/s12885-020-06809-1.

    PMID: 32345242
  2. 2

    The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

    Fazio N, Ungaro A, Spada F, et al.

    Journal of thoracic disease 2017; (9(Suppl 15)):S1501-S1510 doi:10.21037/jtd.2017.06.14.

    PMID: 29201453
  3. 3

    Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide.

    Kos-Kudła B, Ćwikła J, Ruchała M, et al.

    Contemporary oncology (Poznan, Poland) 2017; (21(2)):115-122 doi:10.5114/wo.2017.68619.

    PMID: 28947880
  4. 4

    Transduodenal resection of periampullary neuroendocrine tumor: A case report.

    AlQatari AA, Fallatah RZ, AlQattan AS, et al.

    Annals of medicine and surgery (2012) 2022; (73()):103126 doi:10.1016/j.amsu.2021.103126.

    PMID: 35070273
  5. 5

    Preliminary experience with a new institutional tumor board dedicated to patients with neuroendocrine neoplasms.

    Trikalinos NA, Hammill C, Liu J, et al.

    Abdominal radiology (New York) 2022; (47(12)):4096-4102 doi:10.1007/s00261-022-03707-x.

    PMID: 36266515
  6. 6

    The role of multidisciplinary team meeting histopathology review and its impact on revised reports: Analysis of a national quality improvement program.

    O'Connor E, Treacy A, Mitchell A, Swan N

    American journal of clinical pathology 2024; (161(6)):579-585 doi:10.1093/ajcp/aqad183.

    PMID: 38330196
  7. 7

    Neuroendocrine Neoplasm of the Breast Presenting as a Liver Metastasis: A Rare Diagnostic Challenge.

    Masab M, Gross A, Flanagan M, et al.

    Cureus 2021; (13(8)):e16860 doi:10.7759/cureus.16860.

    PMID: 34513437
  8. 8

    Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database.

    Bonvalot S, Gaignard E, Stoeckle E, et al.

    Annals of surgical oncology 2019; (26(7)):2286-2293 doi:10.1245/s10434-019-07421-9.

    PMID: 31065964
  9. 9

    Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.

    Baeg K, Harris C, Naparst MS, et al.

    BMC cancer 2021; (21(1)):146 doi:10.1186/s12885-021-07868-8.

    PMID: 33563241
  10. 10

    Recurrence of a neuroendocrine tumor of adrenal origin: a case report with more than a decade follow-up.

    Rahmani F, Tohidi M, Dehghani M, et al.

    BMC endocrine disorders 2021; (21(1)):9 doi:10.1186/s12902-020-00673-7.

    PMID: 33413271
  11. 11

    Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.

    Boucher JE, Sommers R

    Clinical journal of oncology nursing 2018; (22(5)):565-568 doi:10.1188/18.CJON.565-568.

    PMID: 30239510
  12. 12

    Cancer Care by Committee to be Superseded by Personal Physician-Patient Partnership Informed by Artificial Intelligence.

    Turner JH

    Cancer biotherapy & radiopharmaceuticals 2023; (38(8)):497-505 doi:10.1089/cbr.2023.0058.

    PMID: 37366774
  13. 13

    Liver metastasis from rectal neuroendocrine neoplasm detected 15 years after primary resection.

    Akabane M, Okubo S, Kinowaki K, et al.

    Surgical case reports 2022; (8(1)):212 doi:10.1186/s40792-022-01569-5.

    PMID: 36459257
  14. 14

    Size matters: Establishing a cut-off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines.

    Kim S, Kim ER, Hong SN, et al.

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2025; (37(9)):962-971 doi:10.1111/den.15056.

    PMID: 40494667
  15. 15

    Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.

    Ito T, Hijioka S, Masui T, et al.

    Journal of gastroenterology 2017; (52(1)):9-18 doi:10.1007/s00535-016-1250-9.

    PMID: 27539256
  16. 16

    Cushing syndrome secondary to a mediastinal carcinoid tumor: a case report.

    Ershadi R, Vahedi M, Jahanbin B, et al.

    International cancer conference journal 2022; (11(2)):152-157 doi:10.1007/s13691-022-00542-1.

    PMID: 35402138
  17. 17

    [Implementation of multidisciplinary team in the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm].

    Zhang P, Shen L

    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2016; (19(11)):1205-1210.

    PMID: 27928786
  18. 18

    Thyroid Hormone Replacement in Patients Following Thyroidectomy for Thyroid Cancer.

    Hannoush ZC, Weiss RE

    Rambam Maimonides medical journal 2016; (7(1)) doi:10.5041/RMMJ.10229.

    PMID: 26886951
  19. 19

    Dose-dependent relationship between levothyroxine and health-related quality of life in survivors of differentiated thyroid cancer.

    Braafladt S, Allison H, Chung J, et al.

    Surgery 2025; (179()):108799 doi:10.1016/j.surg.2024.07.057.

    PMID: 39341744
  20. 20

    Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma.

    Miao Y, Fan K, Peng X, et al.

    Frontiers in endocrinology 2023; (14()):1241145 doi:10.3389/fendo.2023.1241145.

    PMID: 38027203
  21. 21

    Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support in a Patient with Panhypopituitarism: A Case Report.

    Huang D, Kreitler K, Tilton S, et al.

    Cureus 2019; (11(6)):e4995 doi:10.7759/cureus.4995.

    PMID: 31497426
  22. 22

    ENDOCRINE OUTCOMES OF TRANSSPHENOIDAL SURGERY FOR PITUITARY APOPLEXY VERSUS ELECTIVE SURGERY FOR PITUITARY ADENOMA.

    Marcet P, Paluzzi J, Morrison A, Vale FL

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(4)):353-360 doi:10.4158/EP-2018-0488.

    PMID: 30720340
  23. 23

    Clinical/pathological features and survival outcomes of extra-pulmonary neuroendocrine carcinomas: A retrospective single-center series.

    Benini L, Gervaso L, Frassoni S, et al.

    Journal of neuroendocrinology 2025; (37(9)):e70057 doi:10.1111/jne.70057.

    PMID: 40534241
  24. 24

    Neuroendocrine neoplasm update: toward universal nomenclature.

    Rindi G, Inzani F

    Endocrine-related cancer 2020; (27(6)):R211-R218.

    PMID: 32276263
  25. 25

    Complete remission of Cdx-2 positive primary testicular carcinoid tumor: 10-years follow-up and literature review.

    Widmeier E, Füllgraf H, Waller CF

    BMC urology 2020; (20(1)):197 doi:10.1186/s12894-020-00768-2.

    PMID: 33317491
  26. 26

    Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

    Canakis A, Lee LS

    World journal of gastrointestinal endoscopy 2022; (14(5)):267-290 doi:10.4253/wjge.v14.i5.267.

    PMID: 35719897

This page is for informational purposes only and does not replace professional medical advice. Always consult your multidisciplinary tumor board or healthcare provider about your specific treatment and surveillance plan.

Stay up to date

Get notified when new research about Tumor of endocrine glands is published.

No spam. Unsubscribe anytime.